Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

5 trials in Phase 3/4

Results Transparency

22%

2 of 9 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

4(44.4%)

Phase 4

3(33.3%)

Phase 3

2(22.2%)

9Total

N/A(4)

Phase 4(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT01815580Phase 4Completed

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women

Role: collaborator

NCT02744040Not ApplicableCompleted

Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use

Role: collaborator

NCT03043326Unknown

Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women

Role: lead

NCT03757117Phase 4Completed

Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade

Role: lead

NCT02710032Not ApplicableCompleted

TransPrEP: Social Network-Based PrEP Adherence for Transgender Women in Peru

Role: collaborator

NCT01377168Phase 4Completed

Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder

Role: collaborator

NCT01720641Not ApplicableCompleted

Partner Notification Strategies for MSM in Peru

Role: collaborator

NCT01720654Not ApplicableCompleted

Expedited Partner Therapy for MSM in Peru

Role: collaborator

NCT00465205Phase 3Completed

HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons

Role: collaborator

NCT00378976Phase 3Completed

HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.

Role: collaborator

All 10 trials loaded